Anthropic Wants to Develop Its Own Drugs

Anthropic, the company behind the popular AI assistant Claude, is making a bold move into the pharmaceutical industry with the launch of Claude Science. Described as an "AI workbench for scientists," the new platform aims to consolidate fragmented tools and datasets into a single, cohesive environment for drug discovery and scientific research. Claude Science is designed to help researchers accelerate the entire drug development pipeline. It integrates data analysis, literature review, and experiment design into one interface, and can even generate figures and visuals for publications and presentations. This eliminates the need for scientists to constantly switch between different software tools, saving valuable time and reducing the risk of errors. Anthropic is already a dominant player in the AI coding space with its widely adopted tool, Claude Code. Now, the company is leveraging its expertise in large language models to tackle one of the most complex and high-stakes fields: drug development. The goal is to help researchers identify promising drug candidates faster, predict their behavior more accurately, and ultimately bring new treatments to patients more quickly. The move positions Anthropic as a direct competitor to other AI-powered drug discovery platforms, while also raising questions about the role of AI in scientific research. If successful, Claude Science could dramatically shorten the typical 10-15 year timeline for bringing a new drug to market, potentially saving countless lives and billions of dollars in research costs.